Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update.
The gastrin releasing peptide (GRP) receptor is becoming an increasingly attractive target for development of new radiolabeled peptides with diagnostic and therapeutic potential. The attractiveness of the GRP receptor as a target is based upon the functional expression of GRP receptors in several tumors of neuroendocrine origin including prostate, breast, and small cell lung cancer. This concise review outlines some of the efforts currently underway to develop new GRP receptor specific radiopharmaceuticals by employing a variety of radiometal chelation systems.
Smith
C J
CJ
Radiopharmaceutical Sciences Institute, University of Missouri, Columbia, MO 65211, USA.
Volkert
W A
WA
Hoffman
T J
TJ
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001839:Bombesin / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D006801:Humans; D007553:Isotope Labeling / Q000379:methods; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000532:radiotherapy; D011868:Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000627:therapeutic use; D018004:Receptors, Bombesin / Q000378:metabolism*
D014408:Biomarkers, Tumor; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D018004:Receptors, Bombesin; D001839:Bombesin